Related references
Note: Only part of the references are listed.Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
Robert L. Coleman et al.
ONCOLOGIST (2007)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan
Gabrielle Gossner et al.
GYNECOLOGIC ONCOLOGY (2006)
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer:: results of a multicenter phase-II trial
J Sehouli et al.
ANNALS OF ONCOLOGY (2006)
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
D Pectasides et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival
G Ferrandina et al.
GYNECOLOGIC ONCOLOGY (2005)
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers
RJ Kim et al.
GYNECOLOGIC ONCOLOGY (2005)
Current concepts of treatment strategies in advanced or recurrent ovarian cancer
M Salzberg et al.
ONCOLOGY (2005)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
WT Huinink et al.
ANNALS OF ONCOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
SM Eisenkop et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
G D'Agostino et al.
GYNECOLOGIC ONCOLOGY (2003)
A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
DH Smith et al.
ANNALS OF ONCOLOGY (2002)
Relapsed ovarian cancer: Challenges and management strategies for a chronic disease
DK Armstrong
ONCOLOGIST (2002)
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2001)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer
SM Campos et al.
GYNECOLOGIC ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
M Markman et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
